SCHEMBL5535579

SCHEMBL5535579

CC1(CN2CCC(Cc3ccc(C(F)(F)F)cc3)CC2)Cn2cc([N+](=O)[O-])nc2O1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.50
CACNA1C Q13936 1/20 0.50
SCN5A Q14524 1/20 0.50
SLC6A2 P23975 2/20 0.46
SLC6A4 P31645 2/20 0.46
PTGS1 P23219 1/20 0.46
SLC2A1 P11166 1/20 0.44
HIF1A Q16665 1/20 0.37
EPAS1 Q99814 1/20 0.37
CCR5 P51681 1/20 0.36
CHRM1 P11229 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TMEM97 Q5BJF2 2/20 0.35
CCR3 P51677 1/20 0.35
KDM4A O75164 1/20 0.34
KDM4B O94953 1/20 0.34
KDM5C P41229 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
RPS6KB1 P23443 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536656 0.89 KCNH2 (0.66) KCNH2CACNA1CSCN5ASLC6A2SLC6A4
SCHEMBL5536650 0.89 KCNH2 (0.66) KCNH2CACNA1CSCN5ASLC6A2SLC6A4
SCHEMBL5546305 0.89 KCNH2 (0.50) KCNH2CACNA1CSCN5ASLC6A2SLC6A4
SCHEMBL5534791 0.88 KCNH2 (0.49) KCNH2CACNA1CSCN5ASLC6A2SLC6A4
SCHEMBL5534800 0.88 KCNH2 (0.49) KCNH2CACNA1CSCN5ASLC6A2SLC6A4
SCHEMBL5539436 0.88 KCNH2 (0.51) KCNH2CACNA1CSCN5ASLC6A2SLC6A4
SCHEMBL5539438 0.88 KCNH2 (0.51) KCNH2CACNA1CSCN5ASLC6A2SLC6A4
SCHEMBL5539828 0.88 KCNH2 (0.53) KCNH2CACNA1CSCN5ASLC6A2SLC6A4
SCHEMBL5539838 0.88 KCNH2 (0.53) KCNH2CACNA1CSCN5ASLC6A2SLC6A4
SCHEMBL5543362 0.88 KCNH2 (0.53) KCNH2CACNA1CSCN5ASLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KCNH2 3503/4885CACNA1C 3762/4885SCN5A 3856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.